The FLT3 Inhibitor Quizartinib Inhibits ABCG2 at Pharmacologically Relevant Concentrations, with Implications for Both Chemosensitization and Adverse Drug Interactions
Figure 5
Quizartinib increases uptake of fluoroquinolones in cells expressing ABCG2.
K562/ABCG2 (A) and 8226/MR20 (B) cells, overexpressing ABCG2, were incubated with ciprofloxacin at a fixed concentration (25µg/ml) in the absence and presence of quizartinib at a range of concentrations for 30 minutes, and with the ABCG2 transport inhibitor fumitremorgin C (FTC) as a positive control. Cellular fluorescence was measured on a microplate reader. *p<0.05, **p<0.01 and ***p<0.001.